EVENT PULSE PREVIEW: Multiple Sclerosis Market
Event Pulse Previews is a syndicated report series that evaluates current and anticipated trends and practices in hot-button therapeutic areas. These reports provide near- and mid-term outlooks on the shifting landscape of new market entries, treatment algorithms and clinical data.
We are leveraging our multi-faceted healthcare market research platform to conduct an in-depth analysis of physician’s current treatment behaviors in multiple sclerosis, and to predict how treatment decisions may change in the future as a result of anticipated product launches.
REASONS TO PURCHASE
By combining our primary research and proprietary physician panel, we will help our clients answer these key business questions:
- What is the current market share breakdown for each of the existing multiple sclerosis drugs? What are the current trends in prescribing for multiple sclerosis?
- Are neurologists aware of recent launches in multiple sclerosis, including Ampyra for walking and Botox for spasticity?
- What will be the short- and long-term impact of Ampyra and Botox? For which patients have they been prescribed, and which patient groups will likely receive the products in the future?
- How high is the awareness of multiple sclerosis products in development, including Gilenia, cladribine, laquinimod, teriflunomide, CAMPATH, and BG-12? What is the anticipated impact of these potential new drugs?
- What will be the future market share breakdown in multiple sclerosis given recent launches and the potential new market entrants? How will existing drugs be affected?
- What are Managed Care Organization (MCO) Pharmacy Directors’ views regarding coverage for multiple sclerosis drugs? What is their likely response to the products in development?
REPORT DETAILS
Methodology
- Targeted Internet Survey of 75 high-prescribing neurologists
- 10 In-Depth Telephone Interviews with MCO Pharmacy Directors
- Analysis of daily treatment decisions from a panel of 200 neurologists spanning 2005-2010. Analysis will include a breakdown of market share by diagnosis and by physician specialty, and an assessment of how these share levels may shift due to switching behavior to products in development.
Report Contents
-
Current Treatment Practices in Multiple Sclerosis
-
Longitudinal Breakdown of Multiple Sclerosis Market Share by Drug
-
Awareness and Impact of Ampyra
-
Awareness and Impact of Botox
-
Awareness and Impact of Products in Development
-
Anticipated Treatment Practices in Multiple Sclerosis
-
MCOs – Current Formulary for Multiple Sclerosis Drugs
-
MCOs – Response to New Multiple Sclerosis Drugs
-
MCOs – Anticipated Formulary Status for Products in Development
Drugs/Companies That Will be Affected by These Findings:
Marketed
| AMPYRA (dalfampridine) |
Acorda (ACOR) |
| AVONEX (interferon beta-1a) |
Biogen Idec (BIIB) |
| BETASERON (interferon beta-1b) |
Bayer Healthcare |
| BOTOX (onabotulinumtoxina) |
Allergan (AGN) |
| COPAXONE (glatiramer acetate) |
Teva (TEVA) |
| EXTAVIA (interferon beta-1b) |
Novartis (NVS) |
| NOVANTRONE (mitoxantrone) |
EMD Serono |
| REBIF (interferon beta-1a) |
EMD Serono / Pfizer (PFE) |
| TYSABRI (natalizumab) |
Biogen Idec (BIIB) / Elan (ELN) |
In Development
| Gilenia (fingolimod or FTY720) |
Novartis (NVS) |
| Cladribine |
Merck KGaA |
| Campath (alemtuzumab) |
Genzyme (GENZ) |
| BG-12 |
Biogen Idec (BIIB) |
| Laquinimod |
Active Biotech / Teva (TEVA) |
| Teriflunomide |
Sanofi Aventis (SNY) |
For more information, please contact us by clicking HERE.
